Underwater rocks of anti - helicobacter therapy


Cite item

Full Text

Abstract

The publication was prepared to systematize the data of the literature and our own research on the practice of effective eradication therapy of patients with HP-associated diseases. The most significant factors influencing the effective implementation of modern anti-Helicobacter therapy regimens should be adherence of physicians to the use of clinical guidelines, patient adherence to prescriptions and recommendations of specialists, as well as adherence to eradication treatment protocols.

About the authors

M A Livzan

Omsk State Medical University

Email: mlivzan@yandex.ru
д.м.н., проф., зав. каф. факультетской терапии с курсом профессиональных болезней, ректор; ORCID: 0000-0002-6581-7017 Omsk, Russia

References

  1. Maixner F, Krause-Kyora B, Turaev D, Herbig A, Hoopmann M.R, Hallows J.L, Kusebauch U, Vigl E.E, Malfertheiner P, Megraud F, O'Sullivan N, Cipollini G, Coia V, Samadelli M, Engstrand L, Linz B, Moritz R.L, Grimm R, Krause J., Nebel A, Moodley Y, Rattei T, Zink A. The 5300-year - old Helicobacter pylori genome of the Iceman. Science. 2016;351(6269):162-5. doi: 10.1126/science.aad2545
  2. Kao C.Y, Sheu B.S, Wu J.J. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomed J. 2016;39:14-23. doi: 10.1016/j.bj.2015.06.002
  3. Schistosomes, liver flukes and Helicobacter pylori IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241.
  4. Маев И.В., Бакулин И.Г., Курилович С.А., Бакулина Н.В., Андреев Н.Г., Голубев Н.Н. Helicobacter pylori и экстрагастродуоденальные заболевания: доказанные факты и предположения. Доказательная гастроэнтерология. 2018;7(3):45-59. doi: 10.17116/dokgastro2018703145
  5. Franceschi F, Gasbarrini A, Polyzos S.A, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter. 2015;20(Suppl 1):40-6. doi: 10.1111/hel.12256
  6. Kountouras J, Polyzos S.A, Katsinelos P, Zeglinas C, Artemaki F, Tzivras D, Vardaka E, Gavalas E, Romiopoulos I, Simeonidou C, Grigoriadis N, Kountouras C, Dardiotis E, Deretzi G. Cardio - cerebrovascular disease and Helicobacter pylori - related metabolic syndrome: We consider eradication therapy as a potential cardio - cerebrovascular prevention strategy. Int J Cardiol. 2017;229:17-8. doi: 10.1016/j.ijcard.2016.11.265
  7. Wang X.L, Zeng J, Yang Y, Xiong Y, Zhang Z.H, Qiu M, Yan X, Sun X.Y, Tuo Q.Z, Liu R, Wang J.Z. Helicobacter pylori filtrate induces Alzheimer - like tau hyperphosphorylation by activating glycogen synthase kinase-3β. J Alzheimers Dis. 2015;43:153-65. doi: 10.3233/JAD-140198
  8. Ricci V, Romano M, Boquet P. Molecular cross - talk between Helicobacter pylori and human gastric mucosa. World J Gastroenterol. 2011;17(11):1383-99. doi: 10.3748/wjg.v17.i11.1383
  9. Sugano K, Tack J, Kuipers E.J, Graham D.Y, El-Omar E.M, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-67. doi: 10.1136/gutjnl-2015-309252
  10. Hunt R.H, Xiao S.D, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho L.G, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh K.L, Wong B.C, Krabshuis J, Le Mair A, World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20:299-304.
  11. Malfertheiner P, Megraud F, O’Morain C.A, Gisbert J.P, Kuipers E.J, Axon A.T, Bazzoli F, Gasbarrini A, Atherton J, Graham D.Y, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar E.M; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection - the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. doi: 10.1136/gutjnl-2016-312288
  12. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Дехнич Н.Н., Козлов Р.С., Кляритская И.Л., Корочанская Н.В., Курилович С.А., Осипенко М.Ф., Симаненков В.И., Ткачев А.В., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70.
  13. Chey W.D, Leontiadis G.I, Howden C.W, Moss S.F. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212-39. doi: 10.1038/ajg.2016.563
  14. Graham D.Y. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut. 2017;66:2043-6. doi: 10.1136/gutjnl-2017-314744
  15. Zagari R.M, Rabitti S, Eusebi L.H, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest. 2018;48:e12857. doi: 10.1111/eci.12857
  16. Бакулина Н.В., Симаненков В.И., Бакулин И.Г., Ильчишина Т.А. Распространенность хеликобактерной инфекции среди врачей. Экспериментальная и клиническая гастроэнтерология. 2017;12(148):20-4.
  17. Auttajaroon J, Chotivitayatarakorn P, Yamaoka Y, Vilaichone R.K. CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection. Asian Pac J Cancer Prev. 2019;20(4):1243-7. doi: 10.31557/APJCP.2019.20.4.1243
  18. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9.
  19. Maev I.V, Andreev D.N, Kucheryavyi Yu.A, Dicheva D.T. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014;30:134-40. doi: 10.5829/idosi.wasj.2014.30.mett.61
  20. Boltin D, Dotan I, Birkenfeld S. Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational intervention. Ann Gastroenterol. 2019;32(1):52-9. doi: 10.20524/aog.2018.0329
  21. Ribaldone D, Astegiano M, Pellicano R. Helicobacter pylori eradication: poor medical compliance from East to West of the world. Scand J Gastroenterol. 2018;53:265. doi: 10.1080/00365521.2018.1433231
  22. Осипенко М.Ф., Ливзан М.А., Бикбулатова Е.А. «Комплаентность» пациента как один из факторов, определяющих эффективность эрадикационной терапии. Терапевтический архив. 2014;86(2):27-31.
  23. O'Connor H.J. Helicobacter pylori and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits. Aliment Pharmacol Ther. 2002;16(3):487-96. doi: 10.1046/j.1365-2036.2002.01183.x
  24. Бордин Д., Белоусова Н., Воробьёва Н., Зеленикин С. Язвенная болезнь: пути повышения эффективности эрадикации Helicobacter pylori. Врач. 2011;(4):43-7.
  25. Wang C.H, Liao S.T, Yang J, Li C.X, Yang Y.Y, Han R, Chen D.F, Lan C.H. Effects of daily telephone - based re - education before taking medicine on Helicobacter pylori eradication: A prospective single - center study from China. World J Gastroenterol. 2015;21(39):11179-84. doi: 10.3748/wjg.v21.i39.11179
  26. Tang H.L, Li Y, Hu Y.F, Xie H.G, Zhai S.D. Effects of CYP2C19 loss - of - function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitorbased triple therapy regimens: a meta - analysis of randomized clinical trials. Plos One. 2013;8:e62162. doi: 10.1371/journal.pone.0062162
  27. Елохина Е.В., Костенко М.Б., Ливзан М.А., Скальский С.В. Эффективность эрадикационной терапии у пациентов с язвенной болезнью, ассоциированной с Helicobacter pylori, в зависимости от генотипа лекарственного метаболизма ингибиторов протонной помпы. Экспериментальная и клиническая гастроэнтерология. 2015;115(3):31-3.
  28. Villoria A, Garcia P, Calvet X, Gisbert J.P, Vergara M. Meta - analysis: high - dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-77. doi: 10.1111/j.1365-2036.2008.03807.x
  29. Андреев Д.Н., Дичева Д.Т., Маев И.В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017;89(2):84-90. doi: 10.17116/terarkh201789284-90
  30. Graham D.Y, Dore M.P. Update on the use of vonoprazan: a competitive acid blocker. Gastroenterology. 2018;154:462-6. doi: 10.1053/j.gastro.2018.01.018
  31. Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza I, et al. Vonoprazan: a novel and potent alternative in the treatment of acid - related diseases. Dig Dis Sci. 2018;63:302-11. doi: 10.1007/s10620-017-4866-6
  32. Kusunoki M, Yuki M, Ishitobi H, Kobayashi Y, Nagaoka M, Takahashi Y, Fukuba N, Komazawa Y, Shizuku T, Kinoshita Y. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication. Intern Med. 2019 Feb 1. doi: 10.2169/internalmedicine.2233-18
  33. Sugimoto M, Yamaoka Y. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019;9:1560. doi: 10.3389/fphar.2018.01560
  34. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium - competitive acid blocker, as a component of first - line and second - line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double - blind study. Gut. 2016;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304
  35. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The Efficacy and Tolerability of a Triple Therapy Containing a Potas - sium-Competitive Acid Blocker Compared With a 7-Day PPI- Based Low-Dose Clarithromycin Triple Therapy. Am J Gastroenterol. 2016;111(7):949-56. doi: 10.1038/ajg.2016.182
  36. Thung I, Aramin H, Vavinskaya V, Gupta S, Park J.Y, Crowe S.E, Valasek M.A. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-33. doi: 10.1111/apt.13497
  37. Mégraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl A.M, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34-42. doi: 10.1136/gutjnl-2012-302254
  38. Hu Y, Zhu Y, Lu N.H. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017;7:168. doi: 10.3389/fcimb.2017.00168
  39. Pellicano R, Zagari R.M, Zhang S, Saracco G.M, Moss S.F. Pharmacological considerations and step - by - step proposal for the treatment of Helicobacter pylori infection in the year 2018. Minerva Gastroenterol Dietol. 2018;64:310-21. doi: 10.23736/S1121-421X.18.02492-3
  40. Бордин Д.С., Эмбутниекс Ю.В., Вологжанина Л.Г. и др. Европейский регистр Helicobacter pylori (HP-EUREG): как изменилась клиническая практика в России с 2013 по 2018 год. Терапевтический архив. 2019;91(2):16-24. doi: 10.26442/00403660.2019.02.000156
  41. Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic - resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318-27. doi: 10.1016/S1473-3099(17)30753-3
  42. He X, Liao X, Li H, Xia W, Sun H. Bismuth - induced inactivation of ferric uptake regulator from Helicobacter pylori. Inorganic Chem. 2017;56:15041-8. doi: 10.1021/acs.inorgchem.7b02380
  43. Nishizawa T, Nishizawa Y, Yahagi N, et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta - analysis. J Gastroenterol Hepatol. 2014;29(Suppl.4):20-4. doi: 10.1111/jgh.12769
  44. Szajewska H, Horvath A, Kołodziej M. Systematic review with meta - analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41:1237-45. doi: 10.1111/apt.13214
  45. Zou J, Dong J, Yu X. Meta - analysis: Lactobacillus containing quadruple therapy versus standard triple first - line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:97-107. doi: 10.1111/j.1523-5378.2009.00716.x
  46. Sachdeva A, Nagpal J. Meta - analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2009;29:720-30. doi: 10.1111/j.1365-2036.2009.03934.x
  47. Tong J.L, Ran Z.H, Shen J, Zhang C.X, Xiao S.D. Metaanalysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25:155-68. doi: 10.1111/j.1365-2036.2006.03179.x
  48. Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б., Ким В.А., Быстровская Е.В., Шишин К.В. Эффективность и безопасность Lactobacillus Reuteri DSMZ17648 у инфицированных Helicobacter pylori. Лечащий врач. 2016;(5):106.
  49. Hardbower D.M, Peek R.M. Jr, Wilson K.T. At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol. 2014;96(2):201-12. doi: 10.1189/jlb.4BT0214-099R
  50. Niikura R, Hayakawa Y, Hirata Y, Ogura K, Fujishiro M, Yamada A, Ushiku T, Konishi M, Fukayama M, Koike K. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion. Int J Mol Sci. 2019;20(8). pii: E1913. doi: 10.3390/ijms20081913
  51. Ливзан М.А., Мозговой С.И., Кононов А.В. Гастрит после эрадикации Helicobacter pylori - простые следы или серьезные последствия? Лечащий врач. 2011;(7):7.
  52. Ливзан М.А., Кононов А.В., Мозговой С.И. Постэрадикационный период хронического гастрита, ассоциированного с инфекцией Helicobacter pylori. Consilium Medicum. 2008;10(8):15-20.
  53. Ford A.C, Forman D, Hunt R.H, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta - analysis of randomised controlled trials. BMJ. 2014;348:g3174. doi: 10.1136/bmj.g3174
  54. Matysiak-Budnik T, Megraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer. 2006;42(6):708-16. doi: 10.1016/j.ejca.2006.01.020
  55. Kalisperati P, Spanou E, Pateras I.S et al. Inflammation, DNA Damage, Helicobacter pylori and Gastric Tumorigenesis. Front Genet. 2017;8:20. doi: 10.3389/fgene.2017.00020
  56. Graham D.Y, Matsueda S, Shiotani A. Changing the natural history of metachronous gastric cancer after H. pylori eradication. Jpn J Helicobacter Res. 2015;16:42-50.
  57. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004;157:301-11.
  58. Demiray M, Gulten M, Manavoglu O et al. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six - month follow - up study. Hepatogastroenterology. 2004;51(59):1531-5.
  59. Кононов А.В., Ливзан М.А., Мозговой С.И. Гастрит после эрадикации: экс - геликобактерный или постэрадикационный? В кн.: Тезисы докладов Х Российского национального конгресса «Человек и лекарство». М., 2003.
  60. Shimada M, Ina K, Kyokane K, et al. Upregulation of mucosal soluble fas ligand and interferon - gamma may be involved in ulcerogenesis in patients with Helicobacter pylori - positive gastric ulcer. Scand J Gastroenterol. 2002;37(5):501-11. doi: 10.1080/00365520252903026
  61. Маев И.В. Современные представления о заболеваниях желудочно - кишечного тракта, ассоциированных с Helicobacter pylori. Терапевтический архив. 2006;78(2):10-5.
  62. Osawa H, Kita H, Ohnishi H, Mutoh H, Ishino Y, Satoh K, Sugano K. Histamine-2 receptor expression in gastric mucosa before and after Helicobacter pylori cure. Aliment Pharmacol Ther. 2005;21(Suppl.2):92-8. doi: 10.1111/j.1365-2036.2005.02481.x
  63. Cheung K.S, Leung W.K. Risk of gastric cancer development after eradication of Helicobacter pylori. World J Gastrointest Oncol. 2018;10(5):115-23. doi: 10.4251/wjgo.v10.i5.115
  64. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735-40.
  65. Correa P, Piazuelo M.B, Camargo M.C. The future of gastric cancer prevention. Gastric Cancer. 2004;7:9-16. doi: 10.1007/s10120-003-0265-0
  66. Маев И.В., Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Коровина Т.И. Клиническое значение инфекции Helicobacter pylori. Клиническая медицина. 2013;91(8):4-12.
  67. Han X, Jiang K, Wang B, et al. Effect of Rebamipide on the Pre - malignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665-73. doi: 10.1007/s40261-015-0329-z
  68. Tanigawa T, Pai R, Arakawa T, Tarnawski A.S. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci. 2007;52(1):240-7. doi: 10.1007/s10620-006-9226-x
  69. Tsukamoto H, Mizoshita T, Katano T, Hayashi N, Ozeki K, Ebi M, Shimura T, Mori Y, Tanida S, Kataoka H, Tsukamoto T, Tatematsu M, Joh T. Preventive effect of rebamipide on N-methyl-N’-nitro-N-nitrosoguanidine - induced gastric carcinogenesis in rats. Exp Toxicol Pathol. 2015;67(3):271-7. doi: 10.1016/j.etp.2015.01.003
  70. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;86(3):94-9.
  71. Андреев Д.Н., Маев И.В., Дичева Д.Т., Самсонов А.А., Парцваниа-Виноградова Е.В. Эффективность и безопасность применения ребамипида в схеме тройной эрадикационной терапии инфекции Helicobacter pylori: проспективное рандомизированное сравнительное исследование. Терапевтический архив. 2018;90(8):27-32. doi: 10.26442/terarkh201890827-32

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies